PHARMACEUTICAL 2013

Nektar Therapeutics
Rank 150 of 218



RealRate

PHARMACEUTICAL 2013

Nektar Therapeutics
Rank 150 of 218

NEKTAR

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 3.2% points.The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 79% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	314,631
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	78,537
Liabilities, Non-Current	8,407
Other Assets	34,443
Other Compr. Net Income	0
Other Expenses	32,509
Other Liabilities	363,828
Other Net Income	-30,248
Other Revenues	81,191
Property and Equipment	72,215
Research and Development	148,675
Selling, General and Administrative Expense	41,614

Output Variable	Value in 1000 USD
Assets	497,790
Liabilities	450,772
Expenses	222,798
Revenues	81,191
Stockholders Equity	47,018
Net Income	-171,855
Comprehensive Net Income	-171,855
BaseVar	641,400
ECR before LimitedLiability	-15%
Economic Capital Ratio	141%